Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
Eli Lilly and Company , the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and ...
If you're looking for a luxury spa-like experience, you've come to the right place.
People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.
Nearly two-thirds (63%) of Americans with an overdue tax bill owe the IRS at least $10,000, according to a 2026 survey by LendEDU, and over 10% of those carrying tax debt are behind by $100,000 or ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that together with Kite, a Gilead company, it will present more than 25 abstracts, including six oral presentations, at the 2026 ASCO Annual ...
Colon cancer is no longer a disease that only elderly suffer from. Even younger women at the age of 50 are also suffering ...
Statins are one of the most common medications prescribed to people with high cholesterol levels to help manage the condition ...
Statins are among the most widely prescribed medications for those suffering from high cholesterol, helping to manage the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results